Valuation: Erasca, Inc.

Market Cap 5.7B 4.99B 4.6B 4.29B 8.09B 539B 8.24B 55.22B 21.44B 266B 21.4B 20.93B 926B P/E 2026 *
-19x
P/E 2027 * -32.4x
Enterprise Value 5.03B 4.4B 4.06B 3.79B 7.14B 475B 7.26B 48.71B 18.91B 234B 18.88B 18.46B 817B EV / Sales 2026 *
-
EV / Sales 2027 * 9,953x
Free-Float
89.34%
Yield 2026 *
-
Yield 2027 * -
1 day-1.83%
1 week+18.67%
Current month-2.51%
1 month+29.23%
3 months+7.59%
6 months+397.49%
Current year+380.11%
1 week 14.44
Extreme 14.445
18.46
1 month 11.8
Extreme 11.805
18.46
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer - 25/05/2022
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap.
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
06-26Free

Director

29,888 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-1.72%+18.67%+1,213.24%+547.10% 5.7B
+2.77%+6.25%-0.46%+6.04% 47.18B
-0.25%+10.95%+410.61%+602.07% 39.82B
+6.24%+10.92%+26.62%-6.87% 32.25B
+2.92%+4.92%+18.60%+60.77% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
-1.44%+10.81% - - 16.57B
+4.06%+7.20%+71.22%+129.98% 15.12B
-0.15%+2.15%+12.64%+17.55% 13.69B
-1.24%+2.86%+97.07%+91.60% 13.1B
Average +1.14%+8.79%+207.15%+164.35% 23.97B
Weighted average by Cap. +1.80%+7.74%+123.57%+148.98%

Financials

2026 *2027 *
Net sales - 500K 438K 404K 377K 710K 47.28M 723K 4.85M 1.88M 23.33M 1.88M 1.84M 81.27M
Net income -299M -261M -241M -225M -424M -28.23B -432M -2.89B -1.12B -13.93B -1.12B -1.1B -48.53B -189M -166M -153M -143M -269M -17.9B -274M -1.84B -712M -8.83B -711M -696M -30.78B
Net Debt -672M -588M -543M -506M -954M -63.51B -971M -6.51B -2.53B -31.34B -2.52B -2.47B -109B -721M -631M -582M -543M -1.02B -68.14B -1.04B -6.98B -2.71B -33.62B -2.71B -2.65B -117B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
01/07/26 $17.86 -2.51% 1,265,396
30/06/26 $18.32 +0.16% 5,407,603
29/06/26 $18.29 +14.24% 7,991,648
26/06/26 $16.01 +7.09% 18,335,394
25/06/26 $14.95 -0.66% 6,132,666
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.32USD
Average target price
21.00USD
Spread / Average Target
+14.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock